Dr. Mat Legut is the co-founder and CEO of OverT Bio, an immunologist with over a decade of experience spanning cell therapy, oncolytic viruses, antigen discovery, and nanomedicine. Together with Dr. Sanjana, he developed the foundational cell programming and genome-scale overexpression platform that powers OverT's immunotherapies, building on his prior work pioneering pooled overexpression screening as a Hope Fellow at the New York Genome Center and NYU. He completed his PhD in Andrew Sewell's lab at Cardiff University and has authored more than thirty publications and nine patent applications.